News >

Avelumab Improves OS as Frontline Maintenance in Urothelial Carcinoma

Gina Columbus @ginacolumbusonc
Published: Monday, Jan 06, 2020

Chris Boshoff, MD, PhD

Chris Boshoff, MD, PhD
Frontline maintenance therapy with avelumab (Bavencio) plus best supportive care demonstrated a statistically significant improvement in overall survival (OS) compared with best supportive care alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression, meeting the primary endpoint of a planned interim analysis of the phase III JAVELIN Bladder 100 study (NCT02603432).1

The PD-L1 inhibitor demonstrated the survival benefit in both coprimary patient populations, which were all randomized patients and those with PD-L1–positive tumors. Additionally, the safety profile with avelumab was found to be consistent with previous trials of the immunotherapy.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication